摘要
目的:评价黄连制剂对代谢综合征大鼠体重、血压、血糖、血脂等指标的影响。方法:计算机检索CNKI、VIP、CBM、Wangfang、PubMed和Embase数据库,收集黄连制剂治疗大鼠代谢综合征的实验研究。应用RevMan 5.3进行Meta分析,并采用Cochrane风险偏倚评估工具评价方法学质量、GRADE系统评估证据质量级别。结果:纳入9个研究,共165只大鼠。结果显示:黄连为君药的中药复方在改善体质量[MD=-64.55,95%CI(-124.33,-4.77),P=0.03,I^(2)=94%]、收缩压[MD=-7.94,95%CI(-14.99,-0.89),P=0.03,I^(2)=84%]、甘油三酯[MD=-0.40,95%CI(-0.72,-0.07),P=0.02,I^(2)=94%]、高密度脂蛋白胆固醇[MD=0.21,95%CI(0.02,0.40),P=0.03,I^(2)=65%]和空腹血糖[MD=-1.20,95%CI(-1.80,-0.61),P<0.0001,I^(2)=70%]方面均优于对照组,证据质量为“极低”;降低Lee’s指数的疗效优于对照组[MD=-14.97,95%CI(-24.99,-4.95),P=0.003,I^(2)=31%],为“低”质量证据。黄连素在改善体质量[MD=-52.06,95%CI(-95.56,-8.56),P=0.02,I^(2)=94%]、收缩压[MD=-6.41,95%CI(-11.90,-0.92),P=0.02,I^(2)=54%]、甘油三酯[MD=-0.37,95%CI(-0.64,-0.10),P=0.007,I^(2)=82%]方面优于对照组,证据质量为“极低”。结论:黄连为君药的中药复方和黄连素有效改善代谢综合征大鼠的肥胖和高血压,中药复方对血脂紊乱和高血糖的改善优于黄连素,受限于纳入研究方法学和证据的质量,黄连制剂仍需谨慎应用。
Objective:To evaluate the effects ofHuanglianpreparation on body weight,blood pressure,blood glucose and blood lipid in rats with metabolic syndrome.Method:CNKI,VIP,CBM,Wangfang,PubMed and EMBASE databases were searched to collect experimental studies of Huanglian preparations in the treatment of metabolic syndrome in rats.RevMan 5.3 software was used for meta-analysis,Cochrane risk bias assessment tool was used to evaluate the quality of methodology,and GRADE system was used to evaluate the quality of evidence.Result:Nine studies involving 165 rats were included.The results showed that Huanglian as the core of Chinese herbal compound could improve body mass[MD=-64.55,95%CI(-124.33,-4.77),P=0.03,I^(2)=94%],systolic blood pressure[MD=-7.94,95%CI(-14.99,-0.89),P=0.03,I^(2)=84%],triglyceride[MD=-0.40,95%CI(-0.72,-0.07),P=0.02,I^(2)=94%],high density lipoprotein cholesterol[MD=0.21,95%CI(0.02,0.40),P=0.03,I^(2)=65%]and fasting blood glucose[MD=-1.20,95%CI(-1.80,-0.61),P<0.0001,I^(2)=70%],and the quality of evidence was very low.The treatment group was better than the control group in reducing Lee’s index[MD=-14.97,95%CI(-24.99,-4.95),P=0.003,I^(2)=31%],which was low quality evidence.Berberine was superior to the control group in improving body mass[MD=-52.06,95%CI(-95.56,-8.56),P=0.02,I^(2)=94%],systolic blood pressure[MD=-6.41,95%CI(-11.90,-0.92),P=0.02,I^(2)=54%],triglyceride[MD=-0.37,95%CI(-0.64,-0.10),P=0.007,I^(2)=82%],and the quality of evidence was very low.Conclusion:Chinese herbal compound and berberine are effective in improving obesity and hypertension in rats with metabolic syndrome.Chinese herbal compound is better than berberine in improving dyslipidemia and hyperglycemia.Due to the limitations of the included research methodology and the quality of evidence,Huanglian preparations still need to be cautious.application.
作者
何冰
林建鹏
陈冠霖
杜文基
谢建辉
苏子仁
陈远彬
符丽
HE Bing;LIN Jianpeng;CHEN Guanlin;DU Wenji;XIE Jianhui;SU Ziren;CHEN Yuanbin;FU Li(Guangzhou Liwan District Hospital of Chinese Medicine,Guangzhou 510405,China;不详)
出处
《中国医学创新》
CAS
2021年第18期165-171,共7页
Medical Innovation of China
基金
国家自然科学基金项目(82074082)
广东省基础与应用基础研究基金项目(2021A1515011490)
广东省中医院周仲瑛学术经验传承工作室项目(中医二院[2014]89号)
广州市科技计划项目(202002020042)。
